(OHI) Omega Healthcare Investors - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US6819361006
Skilled Nursing, Assisted Living, Care Homes, REIT
Dividends
| Dividend Yield | 5.87% |
| Yield on Cost 5y | 10.60% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 87.3% |
| Payout Ratio | 141.2% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 18.4% |
| Value at Risk 5%th | 29.4% |
| Relative Tail Risk | -2.98% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.89 |
| Alpha | 14.36 |
| CAGR/Max DD | 1.67 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.360 |
| Beta | 0.184 |
| Beta Downside | 0.186 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.47% |
| Mean DD | 4.89% |
| Median DD | 4.90% |
Description: OHI Omega Healthcare Investors October 31, 2025
Omega Healthcare Investors, Inc. (NYSE: OHI) is a publicly traded REIT that finances and owns long-term care properties-primarily skilled-nursing and assisted-living facilities-in the United States and the United Kingdom. As of June 30 2025 the company’s portfolio comprised 1,032 operating facilities across 42 U.S. states, D.C., and the U.K./Jersey, with 289 of those located abroad, and they are managed by 92 distinct operators.
Key performance indicators that investors watch include a reported occupancy rate of roughly 84% (Q2 2025), a dividend yield near 7.2%, and funds-from-operations (FFO) growth of 5% year-over-year, while leverage remains around 6.5× EBITDA. The sector’s outlook is driven by macro trends such as the aging-population boom (U.S. adults 65+ projected to reach 22% by 2035), tightening Medicare/Medicaid reimbursement rules, and the sensitivity of REIT financing costs to prevailing interest-rate movements.
If you want a data-rich, side-by-side comparison of OHI’s valuation and risk metrics against its peers, the ValueRay platform provides a free, interactive dashboard that can help you dig deeper.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (538.7m TTM) > 0 and > 6% of Revenue (6% = 69.0m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 1.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 213.1% (prev 202.0%; Δ 11.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 876.2m > Net Income 538.7m (YES >=105%, WARN >=100%) |
| Net Debt (4.26b) to EBITDA (1.11b) ratio: 3.83 <= 3.0 (WARN <= 3.5) |
| Current Ratio 7.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (308.2m) change vs 12m ago 11.84% (target <= -2.0% for YES) |
| Gross Margin 98.83% (prev 95.33%; Δ 3.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 11.41% (prev 10.57%; Δ 0.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.62 (EBITDA TTM 1.11b / Interest Expense TTM 218.5m) >= 6 (WARN >= 3) |
Altman Z'' 0.26
| (A) 0.23 = (Total Current Assets 2.81b - Total Current Liabilities 357.4m) / Total Assets 10.60b |
| (B) -0.34 = Retained Earnings (Balance) -3.59b / Total Assets 10.60b |
| (C) 0.08 = EBIT TTM 790.3m / Avg Total Assets 10.08b |
| (D) -0.65 = Book Value of Equity -3.48b / Total Liabilities 5.35b |
| Total Rating: 0.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.31
| 1. Piotroski 4.50pt |
| 2. FCF Yield 4.69% |
| 3. FCF Margin 73.11% |
| 4. Debt/Equity 0.99 |
| 5. Debt/Ebitda 3.83 |
| 6. ROIC - WACC (= 2.79)% |
| 7. RoE 11.16% |
| 8. Rev. Trend 53.92% |
| 9. EPS Trend 38.99% |
What is the price of OHI shares?
As of December 04, 2025, the stock is trading at USD 45.68 with a total of 1,397,787 shares traded.
Over the past week, the price has changed by -0.31%, over one month by +8.81%, over three months by +9.27% and over the past year by +23.79%.
Over the past week, the price has changed by -0.31%, over one month by +8.81%, over three months by +9.27% and over the past year by +23.79%.
Is OHI a buy, sell or hold?
Omega Healthcare Investors has received a consensus analysts rating of 3.69.
Therefor, it is recommend to hold OHI.
- Strong Buy: 4
- Buy: 3
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the OHI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.8 | 0.2% |
| Analysts Target Price | 45.8 | 0.2% |
| ValueRay Target Price | 57.6 | 26.1% |
OHI Fundamental Data Overview November 26, 2025
Market Cap USD = 13.69b (13.69b USD * 1.0 USD.USD)
P/E Trailing = 25.0333
P/E Forward = 10.1317
P/S = 11.8992
P/B = 2.643
P/EG = 1.13
Beta = 0.562
Revenue TTM = 1.15b USD
EBIT TTM = 790.3m USD
EBITDA TTM = 1.11b USD
Long Term Debt = 4.99b USD (from longTermDebt, last quarter)
Short Term Debt = 879.1m USD (from shortTermDebt, last fiscal year)
Debt = 4.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.26b USD (from netDebt column, last quarter)
Enterprise Value = 17.94b USD (13.69b + Debt 4.99b - CCE 737.2m)
Interest Coverage Ratio = 3.62 (Ebit TTM 790.3m / Interest Expense TTM 218.5m)
FCF Yield = 4.69% (FCF TTM 840.9m / Enterprise Value 17.94b)
FCF Margin = 73.11% (FCF TTM 840.9m / Revenue TTM 1.15b)
Net Margin = 46.83% (Net Income TTM 538.7m / Revenue TTM 1.15b)
Gross Margin = 98.83% ((Revenue TTM 1.15b - Cost of Revenue TTM 13.5m) / Revenue TTM)
Gross Margin QoQ = 98.88% (prev 98.85%)
Tobins Q-Ratio = 1.69 (Enterprise Value 17.94b / Total Assets 10.60b)
Interest Expense / Debt = 1.16% (Interest Expense 58.1m / Debt 4.99b)
Taxrate = 2.37% (4.48m / 189.4m)
NOPAT = 771.6m (EBIT 790.3m * (1 - 2.37%))
Current Ratio = 7.86 (Total Current Assets 2.81b / Total Current Liabilities 357.4m)
Debt / Equity = 0.99 (Debt 4.99b / totalStockholderEquity, last quarter 5.04b)
Debt / EBITDA = 3.83 (Net Debt 4.26b / EBITDA 1.11b)
Debt / FCF = 5.06 (Net Debt 4.26b / FCF TTM 840.9m)
Total Stockholder Equity = 4.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.08% (Net Income 538.7m / Total Assets 10.60b)
RoE = 11.16% (Net Income TTM 538.7m / Total Stockholder Equity 4.83b)
RoCE = 8.05% (EBIT 790.3m / Capital Employed (Equity 4.83b + L.T.Debt 4.99b))
RoIC = 8.00% (NOPAT 771.6m / Invested Capital 9.65b)
WACC = 5.21% (E(13.69b)/V(18.68b) * Re(6.69%) + D(4.99b)/V(18.68b) * Rd(1.16%) * (1-Tc(0.02)))
Discount Rate = 6.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 9.60%
[DCF Debug] Terminal Value 79.04% ; FCFE base≈765.1m ; Y1≈806.5m ; Y5≈950.8m
Fair Price DCF = 56.37 (DCF Value 16.66b / Shares Outstanding 295.5m; 5y FCF grow 5.91% → 3.0% )
EPS Correlation: 38.99 | EPS CAGR: 46.67% | SUE: 1.59 | # QB: 2
Revenue Correlation: 53.92 | Revenue CAGR: 6.05% | SUE: 0.80 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.47 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.91 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+9.4% | Growth Revenue=+4.8%
P/E Trailing = 25.0333
P/E Forward = 10.1317
P/S = 11.8992
P/B = 2.643
P/EG = 1.13
Beta = 0.562
Revenue TTM = 1.15b USD
EBIT TTM = 790.3m USD
EBITDA TTM = 1.11b USD
Long Term Debt = 4.99b USD (from longTermDebt, last quarter)
Short Term Debt = 879.1m USD (from shortTermDebt, last fiscal year)
Debt = 4.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.26b USD (from netDebt column, last quarter)
Enterprise Value = 17.94b USD (13.69b + Debt 4.99b - CCE 737.2m)
Interest Coverage Ratio = 3.62 (Ebit TTM 790.3m / Interest Expense TTM 218.5m)
FCF Yield = 4.69% (FCF TTM 840.9m / Enterprise Value 17.94b)
FCF Margin = 73.11% (FCF TTM 840.9m / Revenue TTM 1.15b)
Net Margin = 46.83% (Net Income TTM 538.7m / Revenue TTM 1.15b)
Gross Margin = 98.83% ((Revenue TTM 1.15b - Cost of Revenue TTM 13.5m) / Revenue TTM)
Gross Margin QoQ = 98.88% (prev 98.85%)
Tobins Q-Ratio = 1.69 (Enterprise Value 17.94b / Total Assets 10.60b)
Interest Expense / Debt = 1.16% (Interest Expense 58.1m / Debt 4.99b)
Taxrate = 2.37% (4.48m / 189.4m)
NOPAT = 771.6m (EBIT 790.3m * (1 - 2.37%))
Current Ratio = 7.86 (Total Current Assets 2.81b / Total Current Liabilities 357.4m)
Debt / Equity = 0.99 (Debt 4.99b / totalStockholderEquity, last quarter 5.04b)
Debt / EBITDA = 3.83 (Net Debt 4.26b / EBITDA 1.11b)
Debt / FCF = 5.06 (Net Debt 4.26b / FCF TTM 840.9m)
Total Stockholder Equity = 4.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.08% (Net Income 538.7m / Total Assets 10.60b)
RoE = 11.16% (Net Income TTM 538.7m / Total Stockholder Equity 4.83b)
RoCE = 8.05% (EBIT 790.3m / Capital Employed (Equity 4.83b + L.T.Debt 4.99b))
RoIC = 8.00% (NOPAT 771.6m / Invested Capital 9.65b)
WACC = 5.21% (E(13.69b)/V(18.68b) * Re(6.69%) + D(4.99b)/V(18.68b) * Rd(1.16%) * (1-Tc(0.02)))
Discount Rate = 6.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 9.60%
[DCF Debug] Terminal Value 79.04% ; FCFE base≈765.1m ; Y1≈806.5m ; Y5≈950.8m
Fair Price DCF = 56.37 (DCF Value 16.66b / Shares Outstanding 295.5m; 5y FCF grow 5.91% → 3.0% )
EPS Correlation: 38.99 | EPS CAGR: 46.67% | SUE: 1.59 | # QB: 2
Revenue Correlation: 53.92 | Revenue CAGR: 6.05% | SUE: 0.80 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.47 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.91 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+9.4% | Growth Revenue=+4.8%
Additional Sources for OHI Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle